NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma granted stock options and RSUs as employment inducement awards to five new hires and its new principal accounting officer.

Rhea-AI Summary

NewAmsterdam Pharma (NAMS) granted equity inducement awards under its 2024 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4) to several new employees, including its new principal accounting officer.

The Compensation Committee approved share options covering an aggregate of 52,900 ordinary shares, including 38,900 options for five non-executive new hires and 14,000 options for Robert Gunning, Vice President, Controller. The options were granted on September 1, 2026 at an exercise price of $24.92 per share, equal to the closing market price that day, and vest over four years, with 25% after one year and the remainder in 36 monthly installments, subject to continued service. The Committee also granted restricted stock units (RSUs) covering 11,900 ordinary shares, including 8,700 RSUs for the five non-executive hires and 3,200 RSUs for Mr. Gunning. These RSUs, granted on September 1, 2026, vest over three years in equal annual installments, subject to continued service and the terms of the plan and award agreements.

Market Context

NAMS recorded a 0.22% 24-hour reaction to its August 26 clinical-data announcement. Against that his...

Analysis

NAMS recorded a 0.22% 24-hour reaction to its August 26 clinical-data announcement. Against that history, this grant notice offers no efficacy or financial update; recent insider net selling remains a contextual risk.

Key Figures

Inducement options: 38,900 ordinary shares Controller options: 14,000 ordinary shares Exercise price: $24.92 per share +5 more

8 metrics

Inducement options 38,900 ordinary shares Five non-executive new hires

Controller options 14,000 ordinary shares Robert Gunning inducement grant

Exercise price $24.92 per share September 1, 2026 grant date

Option vesting 4 years; 25% after 1 year and 36 monthly installments Subject to continued employee service

Inducement RSUs 8,700 ordinary shares Five non-executive new hires

Controller RSUs 3,200 ordinary shares Robert Gunning inducement grant

RSU grant date September 1, 2026 Restricted stock units

RSU vesting 3 years; one-third annually Subject to continued employee service

Historical Context

5 past events · Latest: Sep 02 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Sep 02	Investor conferences	Neutral	+2.7%	September Wells Fargo and Cantor healthcare conference participation announced
Aug 26	Clinical data	Positive	+0.2%	New obicetrapib development-program data scheduled for ESC Congress presentation
Aug 06	Inducement grants	Neutral	+1.1%	Equity awards granted to three non-executive new hires
Aug 05	Second-quarter earnings	Negative	-0.5%	Lower revenue and wider net loss reported alongside corporate updates
Jul 29	Investor day	Neutral	-0.3%	Investor Day scheduled to discuss obicetrapib and Phase 3 programs

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

NAMS showed mixed reactions to recent announcements, with positive moves following several informational or clinical updates but a decline after the latest earnings report.

Key Terms

ldl-c, cetp inhibitor, restricted stock units, nasdaq listing rule 5635(c)(4)

4 terms

ldl-c medical

"patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol (“LDL-C”)"

LDL-C stands for low-density lipoprotein cholesterol, the portion of cholesterol carried in the blood by LDL particles that is commonly linked to buildup of plaque in arteries—think of it like sticky debris that can clog pipes. Investors care because changes in LDL-C are a key measure used by regulators and clinicians to judge the effectiveness of cardiovascular drugs and devices, shape insurance coverage, and influence market demand for treatments that lower heart attack and stroke risk.

cetp inhibitor medical

"obicetrapib, an oral, low-dose and once-daily CETP inhibitor"

A CETP inhibitor is a medicine that blocks a blood protein responsible for moving cholesterol between different carriers, which typically raises “good” HDL cholesterol and can lower “bad” LDL cholesterol. For investors, these drugs matter because if clinical trials and regulators confirm they reduce heart disease, they can create large new revenue streams for developers; conversely, trial failures or safety concerns can sharply reduce a company’s value, like a promising new tool that must still prove it fixes the problem.

restricted stock units financial

"approved the grant of restricted stock units covering an aggregate of 8,700"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NAARDEN, The Netherlands and MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 38,900 of NewAmsterdam’s ordinary shares to five non-executive new hires, as well as inducement share options covering 14,000 ordinary shares to Robert Gunning, the Company’s new Vice President, Controller, who serves as the Company’s principal accounting officer. The share options were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).

The share options have an exercise price per share equal to $24.92, which represents the closing market price on the Nasdaq Stock Market of the Company’s ordinary shares on September 1, 2026, the grant date. The shares subject to the options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 equal monthly installments thereafter, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The options are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of an option award agreement covering the grant.

The Compensation Committee of NewAmsterdam’s Board of Directors also approved the grant of restricted stock units covering an aggregate of 8,700 of NewAmsterdam’s ordinary shares to five non-executive new hires, as well as the grant of restricted stock units covering 3,200 ordinary shares to Mr. Gunning. The restricted stock units were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the 2024 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units were granted on September 1, 2026. The restricted stock units will vest over three years, with one-third of the restricted stock units vesting on each of the one-year, two-year and three-year anniversaries of the applicable vesting commencement date, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The restricted stock units are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of a restricted stock unit award agreement covering the grant.

About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

FAQ

What equity inducement grants did NewAmsterdam Pharma (NAMS) announce on September 3, 2026?

NewAmsterdam Pharma announced inducement grants of share options covering 52,900 ordinary shares and restricted stock units (RSUs) covering 11,900 ordinary shares to five non-executive new hires and its new Vice President, Controller, under its 2024 Inducement Plan.

How many stock options and RSUs did NewAmsterdam Pharma (NAMS) grant to new employees and to Robert Gunning?

The company granted share options on 38,900 shares to five non-executive new hires and 14,000 options to Robert Gunning. It also granted 8,700 RSUs to the five non-executive hires and 3,200 RSUs to Mr. Gunning.

What is the exercise price and grant date of the NewAmsterdam Pharma (NAMS) inducement stock options?

The inducement stock options have an exercise price of $24.92 per share, equal to the closing market price of NewAmsterdam’s ordinary shares on the Nasdaq Stock Market on September 1, 2026, which is also the grant date.

What are the vesting schedules for the NewAmsterdam Pharma (NAMS) inducement stock options and RSUs?

The options vest over four years, with 25% vesting on the one-year anniversary of the vesting commencement date and the rest in 36 equal monthly installments, subject to continued service. The RSUs vest over three years, one-third on each of the first, second and third anniversaries, also subject to continued service.

Who is Robert Gunning in the NewAmsterdam Pharma (NAMS) inducement grant announcement?

Robert Gunning is NewAmsterdam Pharma’s new Vice President, Controller, serving as the company’s principal accounting officer. He received inducement grants of 14,000 stock options and 3,200 RSUs under the 2024 Inducement Plan.